Eckstein Lisa, Kaldor Jenny C, Stewart Cameron
College of Arts Law and Education, University of Tasmania, Hobart, Australia.
Bellberry Ltd, Eastwood, Australia.
Monash Bioeth Rev. 2025 Jun;43(1):204-224. doi: 10.1007/s40592-025-00248-z. Epub 2025 May 15.
In Australia, Human Research Ethics Committees (HRECs) play a ubiquitous role reviewing human subjects research, as do Institutional Review Boards in the US and elsewhere. While HRECs were established as peer review bodies, we argue they should now be characterised a 'devolved regulator' within the broader context of the regulatory state. We evidence HRECs' regulatory role through three examples of current responsibilities. By categorising HRECs as a regulator, we are able to assess their role through a regulatory lens. Drawing on Reeve and Magnusson's 'regulatory scaffolding' approach, we suggest key ways in which the role provided by HRECs could be improved. These include setting clear roles and responsibilities HREC review; ensuring HREC accountability for the substantive aspects of their decision making; and accountability for trial sponsors who seek review of trials under the Clinical Trials Notification Scheme. Deficits in the above must incur a credible expectation of escalation and review.
在澳大利亚,人类研究伦理委员会(HRECs)在审查人体研究方面发挥着普遍作用,美国及其他地区的机构审查委员会亦是如此。虽然HRECs是作为同行评审机构设立的,但我们认为,在监管国家的更广泛背景下,它们现在应被视为“下放的监管机构”。我们通过当前职责的三个例子来证明HRECs的监管作用。通过将HRECs归类为监管机构,我们能够从监管角度评估它们的作用。借鉴里夫和马格努松的“监管框架”方法,我们提出了可以改进HRECs所发挥作用的关键方法。这些方法包括明确HREC审查的角色和职责;确保HRECs对其决策的实质性方面负责;以及对根据临床试验通知计划寻求试验审查的试验申办者负责。上述方面的不足必须引发对升级和审查的合理预期。